Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thyroid Cancer: Role of RET and Beyond.

Literature DB >> 24782993

Thyroid Cancer: Role of RET and Beyond.

Abstract

Specific thyroid cancer histotypes, such as papillary and medullary thyroid carcinoma, display genetic rearrangements or point mutations of the RET gene, resulting in its oncogenic conversion. The molecular mechanisms mediating RET rearrangement with other genes and the role of partner genes in tumorigenesis have been described. In addition, the RET protein has become a molecular target for medullary thyroid carcinoma treatment.

Entities: Disease Gene

Keywords: Chromosome rearrangements; RET; Receptor tyrosine kinase; Thyroid cancer; Tyrosine kinase inhibitors

Year: 2012 PMID： 24782993 PMCID： PMC3821455 DOI： 10.1159/000336975

Source DB: PubMed Journal: Eur Thyroid J ISSN： 2235-0640

86 in total

Review 1. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.

Authors: B A Ponder
Journal: Cancer Res Date: 1999-04-01 Impact factor: 12.701

2. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors: M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal: Science Date: 2000-10-06 Impact factor: 47.728

3. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Authors: Christopher J Strock; Jong-In Park; Mark Rosen; Craig Dionne; Bruce Ruggeri; Susan Jones-Bolin; Samuel R Denmeade; Douglas W Ball; Barry D Nelkin
Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701

4. Mast cells have a protumorigenic role in human thyroid cancer.

Authors: R M Melillo; V Guarino; E Avilla; M R Galdiero; F Liotti; N Prevete; F W Rossi; F Basolo; C Ugolini; A de Paulis; M Santoro; G Marone
Journal: Oncogene Date: 2010-08-23 Impact factor: 9.867

Review 5. Molecular genetics of multiple endocrine neoplasia types 1 and 2.

Authors: Stephen J Marx
Journal: Nat Rev Cancer Date: 2005-05 Impact factor: 60.716

Review 6. The GDNF/RET signaling pathway and human diseases.

Authors: M Takahashi
Journal: Cytokine Growth Factor Rev Date: 2001-12 Impact factor: 7.638

7. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Authors: Giuditta Cuccuru; Cinzia Lanzi; Giuliana Cassinelli; Graziella Pratesi; Monica Tortoreto; Giovanna Petrangolini; Ettore Seregni; Antonia Martinetti; Diletta Laccabue; Chiara Zanchi; Franco Zunino
Journal: J Natl Cancer Inst Date: 2004-07-07 Impact factor: 13.506

Review 8. Chromosome fragile sites.

Authors: Sandra G Durkin; Thomas W Glover
Journal: Annu Rev Genet Date: 2007 Impact factor: 16.830

9. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting.

Authors: Cristiana Carniti; Carla Perego; Piera Mondellini; Marco Alessandro Pierotti; Italia Bongarzone
Journal: Cancer Res Date: 2003-05-01 Impact factor: 12.701

10. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

Authors: Francesca Carlomagno; Teresa Guida; Suresh Anaganti; Livia Provitera; Svend Kjaer; Neil Q McDonald; Anderson J Ryan; Massimo Santoro
Journal: Endocr Relat Cancer Date: 2008-11-24 Impact factor: 5.678

5 in total

1. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.

Authors: Alessia Lopergolo; Rosalba Perrone; Monica Tortoreto; Filippo Doria; Giovanni L Beretta; Valentina Zuco; Mauro Freccero; Maria Grazia Borrello; Cinzia Lanzi; Sara N Richter; Nadia Zaffaroni; Marco Folini
Journal: Oncotarget Date: 2016-08-02

2. Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer.

Authors: Selina K Wong; Quincy S C Chu; Jennifer L Spratlin; Randeep Sangha; Alexander J B McEwan; Donald W Morrish; Diane Arndt; Gwen Sergenson; Adriaan Cleton; Funan Huang; Michael B Sawyer
Journal: Case Rep Oncol Date: 2019-10-16

3. Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study.

Authors: Xiangqian Zheng; Qinghai Ji; Yuping Sun; Minghua Ge; Bin Zhang; Ying Cheng; Shangtong Lei; Feng Shi; Ye Guo; Linfa Li; Lu Chen; Jingxin Shao; Wanli Zhang; Ming Gao
Journal: Ther Adv Med Oncol Date: 2022-08-29 Impact factor: 5.485

4. Comparison of pediatric and adult medullary thyroid carcinoma based on SEER program.

Authors: Zhuang Zhao; Xiang-Dang Yin; Xu-He Zhang; Zhi-Wen Li; Dun-Wei Wang
Journal: Sci Rep Date: 2020-08-06 Impact factor: 4.379

5. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.

Authors: Min Li; Haitao Jia; Qiuqin Qian; Peng Wen; Chuan Chen; Yaqiong Hua; Kai Wang; Wenyong Zhang; Feng Shi
Journal: Diagn Pathol Date: 2020-05-11 Impact factor: 2.644

5 in total